Nuvalent, Inc. (NUVL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Nuvalent, Inc. (NUVL)
Company Performance

Current Price

as of Oct 16, 2024

$104.81

P/E Ratio

N/A

Market Cap

$6.75B

Description

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerNUVL
  • Price$104.81+2.33%

Trading Information

  • Market Cap$6.75B
  • Float55.38%
  • Average Daily Volume (1m)513,765
  • Average Daily Volume (3m)452,596
  • EPS-$2.78

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$57.17M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$65.15M
  • EV$4.24B
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B10.65
Documents